RT Conference Proceedings
T1 Pooled analysis of patient (pt)-reported quality of life (QOL) in the MONALEESA (ML)-2,-3, and-7 trials of ribociclib (RIB) plus endocrine therapy (ET) to treat hormone receptore-positive, HER2-negative (HR+/HER2L) advanced breast cancer (ABC)
A1 Fasching, P. A.
A1 Bardia, A.
A1 Nusch, A.
A1 Jerusalem, G.
A1 Chan, A.
A1 El Saghir, N.
A1 Alba, E.
A1 Im, S-A.
A1 Janni, W.
A1 Chandiwana, D.
A1 Lanoue, B.
A1 Thuerigen, A.
A1 Gaur, A.
A1 Harbeck, N.
PB Elsevier
SN 0923-7534
YR 2020
FD 2020-09-01
LK https://hdl.handle.net/10668/26855
UL https://hdl.handle.net/10668/26855
LA en
DS RISalud
RD Apr 7, 2025